 Kazia Therapeutics Ltd ASX:KZA, NASDAQ:KZIA, a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib a first-line therapy in patients with glioblastoma. The company reports that these results confirm the assets previously reported safety and efficacy markers, and the company has high hopes that this signals a breakthrough in the treatment of a complex disease of high unmet need. 